المؤلفون: Kondili, Loreta A, Zanetto, Alberto, Quaranta, Maria Giovanna, Ferrigno, Luigina, Panetta, Valentina, Calvaruso, Vincenza, Zignego, Anna Linda, Brunetto, Maurizia R, Raimondo, Giovanni, Biliotti, Elisa, Ieluzzi, Donatella, Iannone, Andrea, Madonia, Salvatore, Chemello, Liliana, Cavalletto, Luisa, Coppola, Carmine, Morisco, Filomena, Barbaro, Francesco, Licata, Anna, Federico, Alessandro, Cerini, Federica, Persico, Marcello, Pompili, Maurizio, Ciancio, Alessia, Piscaglia, Fabio, Chessa, Luchino, Giacometti, Andrea, Invernizzi, Pietro, Brancaccio, Giuseppina, Benedetti, Antonio, Baiocchi, Leonardo, Gentile, Ivan, Coppola, Nicola, Nardone, Gerardo, Craxì, Antonio, Russo, Francesco Paolo

المساهمون: Kondili, Loreta A, Zanetto, Alberto, Quaranta, Maria Giovanna, Ferrigno, Luigina, Panetta, Valentina, Calvaruso, Vincenza, Zignego, Anna Linda, Brunetto, Maurizia R, Raimondo, Giovanni, Biliotti, Elisa, Ieluzzi, Donatella, Iannone, Andrea, Madonia, Salvatore, Chemello, Liliana, Cavalletto, Luisa, Coppola, Carmine, Morisco, Filomena, Barbaro, Francesco, Licata, Anna, Federico, Alessandro, Cerini, Federica, Persico, Marcello, Pompili, Maurizio, Ciancio, Alessia, Piscaglia, Fabio, Chessa, Luchino, Giacometti, Andrea, Invernizzi, Pietro, Brancaccio, Giuseppina, Benedetti, Antonio, Baiocchi, Leonardo, Gentile, Ivan, Coppola, Nicola, Nardone, Gerardo, Craxì, Antonio, Russo, Francesco Paolo

مصطلحات موضوعية: coagulation, direct‐acting antiviral, long term outcome, predictive factor, real‐life cohort

الوصف: Background & Aims: Sustained virological response (SVR) by direct-acting antivirals (DAAs) may reverse the hypercoagulable state of HCV cirrhosis and the portal vein thrombosis (PVT) risk. We evaluated the incidence and predictive factors of de novo, non-tumoral PVT in patients with cirrhosis after HCV eradication.Methods: Patients with HCV-related cirrhosis, consecutively enrolled in the multi-center ongoing PITER cohort, who achieved the SVR using DAAs, were prospectively evaluated. Kaplan-Meier and competing risk regression analyses were performed.Results: During a median time of 38.3 months (IQR: 25.1-48.7 months) after the end of treatment (EOT), among 1609 SVR patients, 32 (2.0%) developed de novo PVT. A platelet count <= 120,000/mu L, albumin levels <= 3.5 mg/dL, bilirubin >1.1 mg/dL, a previous liver decompensation, ALBI, Baveno, FIB-4, and RESIST scores were significantly different (p < 0.001), among patients who developed PVT versus those who did not. Considering death and liver transplantation as competing risk events, esophageal varices (subHR: 10.40; CI 95% 4.33-24.99) and pre-treatment ALBI grade >= 2 (subHR: 4.32; CI 95% 1.36-13.74) were independent predictors of PVT. After HCV eradication, a significant variation in PLT count, albumin, and bilirubin (p < 0.001) versus pre-treatment values was observed in patients who did not develop PVT, whereas no significant differences were observed in those who developed PVT (p > 0.05). After the EOT, esophageal varices and ALBI grade >= 2, remained associated with de novo PVT (subHR: 9.32; CI 95% 3.16-27.53 and subHR: 5.50; CI 95% 1.67-18.13, respectively).Conclusions: In patients with HCV-related cirrhosis, a more advanced liver disease and significant portal hypertension are independently associated with the de novo PVT risk after SVR.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/38032175; info:eu-repo/semantics/altIdentifier/wos/WOS:001112384100001; volume:12; issue:3; journal:UNITED EUROPEAN GASTROENTEROLOGY JOURNAL; https://hdl.handle.net/11577/3512420Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85178249344

الإتاحة: https://doi.org/10.1002/ueg2.12496Test
https://hdl.handle.net/11577/3512420Test

المؤلفون: Giannini, Edoardo G., Pasta, Andrea, Pieri, Giulia, Plaz-Torres, Maria Corina, Marseglia, Mariarosaria, Pelizzaro, Filippo, Sangiovanni, Angelo, Cabibbo, Giuseppe, Ghittoni, Giorgia, Di Marco, Mariella, Foschi, Francesco Giuseppe, Guarino, Maria, Biasini, Elisabetta, Saitta, Carlo, Campani, Claudia, Svegliati‐Baroni, Gianluca, Gasbarrini, Antonio, Brunetto, Maurizia Rossana, Magalotti, Donatella, Azzaroli, Francesco, Mega, Andrea, Sacco, Rodolfo, Nardone, Gerardo, Sacerdoti, David, Masotto, Alberto, Vidili, Gianpaolo, Bucci, Laura, Vitale, Alessandro, Trevisani, Franco

المساهمون: Giannini, Edoardo G., Pasta, Andrea, Pieri, Giulia, Plaz-Torres, Maria Corina, Marseglia, Mariarosaria, Pelizzaro, Filippo, Sangiovanni, Angelo, Cabibbo, Giuseppe, Ghittoni, Giorgia, Di Marco, Mariella, Foschi, Francesco Giuseppe, Guarino, Maria, Biasini, Elisabetta, Saitta, Carlo, Campani, Claudia, Svegliati‐baroni, Gianluca, Gasbarrini, Antonio, Brunetto, Maurizia Rossana, Magalotti, Donatella, Azzaroli, Francesco, Mega, Andrea, Sacco, Rodolfo, Nardone, Gerardo, Sacerdoti, David, Masotto, Alberto, Vidili, Gianpaolo, Bucci, Laura, Vitale, Alessandro, Trevisani, Franco

مصطلحات موضوعية: liver transplantation, outcome, survival, treatment

الوصف: Background & Aims: Chronic hepatitis D virus (HDV) often leads to end-stage liver disease and hepatocellular carcinoma (HCC). Comprehensive data pertaining to large populations with HDV and HCC are missing, therefore we sought to assess the characteristics, management, and outcome of these patients, comparing them to patients with hepatitis B virus (HBV) infection. Methods: We analysed the Italian Liver Cancer database focusing on patients with positivity for HBV surface antigen and anti-HDV antibodies (HBV/HDV, n = 107) and patients with HBV infection alone (n = 588). Clinical and oncological characteristics, treatment, and survival were compared in the two groups. Results: Patients with HBV/HDV had worse liver function [Model for End-stage Liver Disease score: 11 vs. 9, p < .0001; Child-Turcotte-Pugh score: 7 vs. 5, p < .0001] than patients with HBV. HCC was more frequently diagnosed during surveillance (72.9% vs. 52.4%, p = .0002), and the oncological stage was more frequently Milan-in (67.3% vs. 52.7%, p = .005) in patients with HBV/HDV. Liver transplantation was more frequently performed in HBV/HDV than in HBV patients (36.4% vs. 9.5%), while the opposite was observed for resection (8.4% vs. 20.1%, p < .0001), and in a competing risk analysis, HBV/HDV patients had a higher probability of receiving transplantation, independently of liver function and oncological stage. A trend towards longer survival was observed in patients with HBV/HDV (50.4 vs. 44.4 months, p = .106). Conclusions: In patients with HBV/HDV, HCC is diagnosed more frequently during surveillance, resulting in a less advanced cancer stage in patients with more deranged liver function than HBV alone. Patients with HBV/HDV have a heightened benefit from liver transplantation, positively influencing survival.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/38426262; info:eu-repo/semantics/altIdentifier/wos/WOS:001178586100001; numberofpages:12; journal:LIVER INTERNATIONAL; https://hdl.handle.net/11577/3511343Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85186887539

الإتاحة: https://doi.org/10.1111/liv.15855Test
https://hdl.handle.net/11577/3511343Test

المؤلفون: Stefanini, Benedetta, Bucci, Laura, Santi, Valentina, Reggidori, Nicola, Lani, Lorenzo, Granito, Alessandro, Pelizzaro, Filippo, Cabibbo, Giuseppe, Di Marco, Mariella, Ghittoni, Giorgia, Campani, Claudia, Svegliati-Baroni, Gianluca, Foschi, Francesco Giuseppe, Giannini, Edoardo G., Biasini, Elisabetta, Saitta, Carlo, Magalotti, Donatella, Sangiovanni, Angelo, Guarino, Maria, Gasbarrini, Antonio, Rapaccini, Gian Ludovico, Masotto, Alberto, Sacco, Rodolfo, Vidili, Gianpaolo, Mega, Andrea, Azzaroli, Francesco, Nardone, Gerardo, Brandi, Giovanni, Sabbioni, Simone, Vitale, Alessandro, Trevisani, Franco

المساهمون: Stefanini, Benedetta, Bucci, Laura, Santi, Valentina, Reggidori, Nicola, Lani, Lorenzo, Granito, Alessandro, Pelizzaro, Filippo, Cabibbo, Giuseppe, Di Marco, Mariella, Ghittoni, Giorgia, Campani, Claudia, Svegliati-Baroni, Gianluca, Foschi, Francesco Giuseppe, Giannini, Edoardo G., Biasini, Elisabetta, Saitta, Carlo, Magalotti, Donatella, Sangiovanni, Angelo, Guarino, Maria, Gasbarrini, Antonio, Rapaccini, Gian Ludovico, Masotto, Alberto, Sacco, Rodolfo, Vidili, Gianpaolo, Mega, Andrea, Azzaroli, Francesco, Nardone, Gerardo, Brandi, Giovanni, Sabbioni, Simone, Vitale, Alessandro, Trevisani, Franco

مصطلحات موضوعية: Child-Pugh B, Hepatocellular carcinoma, Metronomic capecitabine, Sorafenib

الوصف: Background and aims: The efficacy of systemic therapy for unresectable advanced hepatocellular carcinoma (aHCC) has not been proven in patients with Child-Pugh (C-P) B cirrhosis. Nevertheless, in real-world these patients are treated both with tyrosine kinase inhibitors (TKIs) and with metronomic capecitabine (MC). This study aimed to compare sorafenib and MC outcomes versus best supportive care (BSC) in C-P B patients. Method: Between 2008 and 2020, among 774 C-P B patients with aHCC not amenable/responsive to locoregional treatments, 410 underwent sorafenib, 62 MC, and 302 BSC. The propensity score matching method was used to correct the baseline unbalanced prognostic factors. Results: In the unmatched population, median OS was 9.7 months in patients treated with sorafenib, 8.0 with MC, and 3.9 months with BSC. In sorafenib vs. BSC-matched patients (135 couples), median OS was 7.3 (4.9-9.6) vs. 3.9 (2.6-5.2) months (p<0.001). ECOG-Performance Status, tumor size, macrovascular invasion, AFP, treatment-naive, and sorafenib were independent predictors of survival. In MC vs. BSC-matched patients (40 couples), median OS was 9.0 (0.2-17.8) vs.3.0 (2.2-3.8) months (p<0.001). Median OS did not differ (p = 0.283) in sorafenib vs. MC-matched patients (55 couples). Conclusion: C-P B patients with aHCC undergoing BSC have poor survival. Both Sorafenib and MC treatment improve their prognosis.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/38341377; numberofpages:10; journal:DIGESTIVE AND LIVER DISEASE; https://hdl.handle.net/11577/3511341Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85184761243

الإتاحة: https://doi.org/10.1016/j.dld.2024.01.199Test
https://hdl.handle.net/11577/3511341Test

المؤلفون: Pierannunzio, Daniela, Spinelli, Angela, Berchialla, Paola, Borraccino, Alberto, Charrier, Lorena, Dalmasso, Paola, Lazzeri, Giacomo, Vieno, Alessio, Ciardullo, Silvia, Nardone, Paola

المساهمون: Pierannunzio, Daniela, Spinelli, Angela, Berchialla, Paola, Borraccino, Alberto, Charrier, Lorena, Dalmasso, Paola, Lazzeri, Giacomo, Vieno, Alessio, Ciardullo, Silvia, Nardone, Paola

مصطلحات موضوعية: HBSC, adolescent, physical activity, psychosocial wellbeing

الوصف: The aim of this study was to describe physical activity, both moderate-to-vigorous physical activity (MVPA) and vigorous physical activity (VPA), in a large nationally representative sample of Italian adolescents, aged 11, 13 and 15, and to evaluate if Italian adolescents were in line with the 2020 WHO recommendations. In order to assess the possible impact of physical activity on adolescent psychological and social wellbeing, the associations between MVPA and VPA with life satisfaction, self-rated health and peer relationships were also explored. Data from the 2018 Italian Health Behaviour in School-aged Children (HBSC) survey on 58,976 adolescents were analysed. Logistic regression analysis was used to investigate the association between physical activity and self-rated health, life satisfaction and peer relationships. The association of the Family Affluence Scale with self-rated health, life satisfaction and peer relationships was also studied. The results showed that the majority of Italian adolescents did not meet current physical activity WHO guidelines on MPVA. The prevalence of adolescents claiming to be involved "at least four or more times per week" in VPA was 29%. Overall, our findings highlighted a positive association between MVPA and VPA and life satisfaction, self-rated health and peer support. Data from this study underlined the need to encourage physical activity, especially among older adolescents and girls, who claimed lower levels of MPVA and VPA.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35457667; info:eu-repo/semantics/altIdentifier/wos/WOS:000787014100001; volume:19; issue:8; firstpage:4799; journal:INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH; https://hdl.handle.net/11577/3474343Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85128187723

الإتاحة: https://doi.org/10.3390/ijerph19084799Test
https://hdl.handle.net/11577/3474343Test

المؤلفون: Charrier, Lorena, Bersia, Michela, Vieno, Alessio, Comoretto, Rosanna Irene, Štelemėkas, Mindaugas, Nardone, Paola, Baška, Tibor, Dalmasso, Paola, Berchialla, Paola

المساهمون: Charrier, Lorena, Bersia, Michela, Vieno, Alessio, Comoretto, Rosanna Irene, Štelemėkas, Mindauga, Nardone, Paola, Baška, Tibor, Dalmasso, Paola, Berchialla, Paola

مصطلحات موضوعية: Bayesian longitudinal model, adolescent, alcohol, drinking, forecast, risk behaviour, trend

الوصف: (1) Aim: To summarize alcohol trends in the last 30 years (1985/6-2017/8) among 15-year-olds in Health Behaviour in School-aged Children (HBSC) countries (overall sample size: 413,399 adolescents; 51.55% girls) and to forecast the potential evolution in the upcoming 2021/22 HBSC survey. (2) Methods: Using 1986-2018 prevalence data on weekly alcohol consumption among 15-year-olds related to 40 HBSC countries/regions, a Bayesian semi-parametric hierarchical model was adopted to estimate trends making a clusterization of the countries, and to give estimates for the 2022 HBSC survey. (3) Results: An overall declining trend in alcohol consumption was observed over time in almost all the countries. However, compared to 2014, some countries showed a new increase in 2018 and 2021/22 estimates forecast a slight increase in the majority of countries, pointing out a potential bounce after a decreasing period in frequent drinking habits. (4) Conclusions: The clusterization suggested a homogenization of consumption habits among HBSC countries. The comparison between 2022 observed and expected data could be helpful to investigate the effect of risk behaviour determinants, including the pandemic impact, occurring between the last two waves of the survey.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35270429; info:eu-repo/semantics/altIdentifier/wos/WOS:000773067000001; volume:19; issue:5; firstpage:2737; journal:INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH; https://hdl.handle.net/11577/3474342Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85125231323

الإتاحة: https://doi.org/10.3390/ijerph19052737Test
https://hdl.handle.net/11577/3474342Test

المؤلفون: Turco, Elisa Maria, Giovenale, Angela Maria Giada, Sireno, Laura, Mazzoni, Martina, Cammareri, Alessandra, Marchioretti, Caterina, Goracci, Laura, Di Veroli, Alessandra, Marchesan, Elena, D'Andrea, Daniel, Falconieri, Antonella, Torres, Barbara, Bernardini, Laura, Magnifico, Maria Chiara, Paone, Alessio, Rinaldo, Serena, Della Monica, Matteo, D'Arrigo, Stefano, Postorivo, Diana, Nardone, Anna Maria, Zampino, Giuseppe, Onesimo, Roberta, Leoni, Chiara, Caicci, Federico, Raimondo, Domenico, Binda, Elena, Trobiani, Laura, De Jaco, Antonella, Tata, Ada Maria, Ferrari, Daniela, Cutruzzolà, Francesca, Mazzoccoli, Gianluigi, Ziviani, Elena, Pennuto, Maria, Vescovi, Angelo Luigi, Rosati, Jessica

المساهمون: Turco, Elisa Maria, Giovenale, Angela Maria Giada, Sireno, Laura, Mazzoni, Martina, Cammareri, Alessandra, Marchioretti, Caterina, Goracci, Laura, Di Veroli, Alessandra, Marchesan, Elena, D'Andrea, Daniel, Falconieri, Antonella, Torres, Barbara, Bernardini, Laura, Magnifico, Maria Chiara, Paone, Alessio, Rinaldo, Serena, Della Monica, Matteo, D'Arrigo, Stefano, Postorivo, Diana, Nardone, Anna Maria, Zampino, Giuseppe, Onesimo, Roberta, Leoni, Chiara, Caicci, Federico, Raimondo, Domenico, Binda, Elena, Trobiani, Laura, De Jaco, Antonella, Tata, Ada Maria, Ferrari, Daniela, Cutruzzolà, Francesca, Mazzoccoli, Gianluigi, Ziviani, Elena, Pennuto, Maria, Vescovi, Angelo Luigi, Rosati, Jessica

مصطلحات موضوعية: Human, Haploinsufficiency, Lipid Metabolism, Transcription Factor, Trans-Activator, Phenotype, Autophagy, Tretinoin, Lipid, Smith-Magenis Syndrome

الوصف: Smith-Magenis syndrome (SMS) is a neurodevelopmental disorder characterized by cognitive and behavioral symptoms, obesity, and sleep disturbance, and no therapy has been developed to alleviate its symptoms or delay disease onset. SMS occurs due to haploinsufficiency of the retinoic acid-induced-1 (RAI1) gene caused by either chromosomal deletion (SMS-del) or RAI1 missense/nonsense mutation. The molecular mechanisms underlying SMS are unknown. Here, we generated and characterized primary cells derived from four SMS patients (two with SMS-del and two carrying RAI1 point mutations) and four control subjects to investigate the pathogenetic processes underlying SMS. By combining transcriptomic and lipidomic analyses, we found altered expression of lipid and lysosomal genes, deregulation of lipid metabolism, accumulation of lipid droplets, and blocked autophagic flux. We also found that SMS cells exhibited increased cell death associated with the mitochondrial pathology and the production of reactive oxygen species. Treatment with N-acetylcysteine reduced cell death and lipid accumulation, which suggests a causative link between metabolic dyshomeostasis and cell viability. Our results highlight the pathological processes in human SMS cells involving lipid metabolism, autophagy defects and mitochondrial dysfunction and suggest new potential therapeutic targets for patient treatment.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36411275; info:eu-repo/semantics/altIdentifier/wos/WOS:000886207500001; volume:13; issue:11; firstpage:981; journal:CELL DEATH & DISEASE; https://hdl.handle.net/11577/3462265Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85142392229

الإتاحة: https://doi.org/10.1038/s41419-022-05410-7Test
https://hdl.handle.net/11577/3462265Test

المؤلفون: Borraccino A., Lo Moro G., Dalmasso P., Nardone P., Donati S., Berchialla P., Charrier L., Lenzi M., Spinelli A., Lemma P.

المساهمون: Borraccino, A., Lo Moro, G., Dalmasso, P., Nardone, P., Donati, S., Berchialla, P., Charrier, L., Lenzi, M., Spinelli, A., Lemma, P.

مصطلحات موضوعية: Adolescent health, Sexual behaviour, Sexual health, Social environment, Adolescent, Contraception Behavior, Family, Female, Human, Male, Peer Influence, School Teacher, Sexual Behavior, Social Support, Adolescent Behavior

الوصف: Objective. The aim was to investigate the role of different forms of social support in early sexual intercourse and contraceptive use. Materials and methods. The study sample included 18,918 15-year-olds who took part in the 2018 Italian Health Behaviour in School-aged Children study. Multivariable multilevel logistic regressions were performed taking into account geographical region and socioeconomic status. Results. 21.7% of adolescents reported early sexual intercourse. 71.9% used a condom at last sexual intercourse, 12.2% oral contraceptives 41.2% other contraceptive methods (multiple response question). High support from family and from teachers were associated with a lower likelihood of early sexual intercourse in both genders, while peer support was shown to increase this likelihood among boys. Adolescents with high social support were more likely to use condoms. Conclusions. Social support can have a positive influence on adolescents' sexual behaviour. Sexual education programmes should aim to engage peers and those significant adults who can influence adolescents' lives, in and out of school.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33346181; info:eu-repo/semantics/altIdentifier/wos/WOS:000604989400017; volume:56; issue:4; firstpage:522; lastpage:530; numberofpages:9; journal:ANNALI DELL'ISTITUTO SUPERIORE DI SANITÀ; http://hdl.handle.net/11577/3448986Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85098745210

الإتاحة: https://doi.org/10.4415/ANN_20_04_17Test
http://hdl.handle.net/11577/3448986Test

المؤلفون: Nardone, Olga Maria, Calabrese, Giulio, Barberio, Brigida, Giglio, Mariano Cesare, Castiglione, Fabiana, Luglio, Gaetano, Savarino, Edoardo, Ghosh, Subrata, Iacucci, Marietta

المساهمون: Nardone, Olga Maria, Calabrese, Giulio, Barberio, Brigida, Giglio, Mariano Cesare, Castiglione, Fabiana, Luglio, Gaetano, Savarino, Edoardo, Ghosh, Subrata, Iacucci, Marietta

مصطلحات موضوعية: Crohn’s disease, Kono-S anastomosi, conventional anastomosi, endoscopic recurrence, postoperative recurrence

الوصف: Background: Patients with Crohn's disease (CD) after ileocolic resection may develop an endoscopic postoperative recurrence (ePOR) that reaches 40% to 70% of incidence within 6 months. Recently, there has been growing interest in the potential effect of anastomotic configurations on ePOR. Kono-S anastomosis has been proposed for reducing the risk of clinical and ePOR. Most studies have assessed the association of ileocolonic anastomosis and ePOR individually, while there is currently limited data simultaneously comparing several types of anastomosis. Therefore, we performed a systematic review and meta-analysis to assess the impact of different ileocolonic anastomosis on ePOR in CD.Methods: We searched PubMed and Embase from inception to January 2023 for eligible studies reporting the types of anastomoses and, based on these, the rate of endoscopic recurrence at >= 6 months. Studies were grouped by conventional anastomosis, including side-to-side, end-to-end, and end-to-side vs Kono-S, and comparisons were made between these groups. Pooled incidence rates of ePOR were computed using random-effect modelling.Results: Seventeen studies, with 2087 patients who underwent ileocolic resection for CD were included. Among these patients, 369 (17,7%) Kono-S anastomoses were performed, while 1690 (81,0%) were conventional ileocolic anastomosis. Endoscopic postoperative recurrence at >= 6 months showed a pooled incidence of 37.2% (95% CI, 27.7-47.2) with significant heterogeneity among the studies (P < .0001). In detail, patients receiving a Kono-S anastomosis had a pooled incidence of ePOR of 24.7% (95% CI, 6.8%-49.4%), while patients receiving a conventional anastomosis had an ePOR of 42.6% (95% CI, 32.2%-53.4%).Conclusions: Kono-S ileocolic anastomosis was more likely to decrease the risk of ePOR at >= 6 months compared with conventional anastomosis. Our findings highlight the need to implement the use of Kono-S anastomosis, particularly for difficult to treat patients. However, results from larger randomized ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37931290; info:eu-repo/semantics/altIdentifier/wos/WOS:001099874200001; journal:INFLAMMATORY BOWEL DISEASES; https://hdl.handle.net/11577/3505910Test

الإتاحة: https://doi.org/10.1093/ibd/izad252Test
https://hdl.handle.net/11577/3505910Test

المؤلفون: Vitale, Alessandro, Svegliati-Baroni, Gianluca, Ortolani, Alessio, Cucco, Monica, Dalla Riva, Giulio V, Giannini, Edoardo G, Piscaglia, Fabio, Rapaccini, Gianludovico, Di Marco, Mariella, Caturelli, Eugenio, Zoli, Marco, Sacco, Rodolfo, Cabibbo, Giuseppe, Marra, Fabio, Mega, Andrea, Morisco, Filomena, Gasbarrini, Antonio, Foschi, Francesco Giuseppe, Missale, Gabriele, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Azzaroli, Francesco, Vidili, Gianpaolo, Oliveri, Filippo, Pelizzaro, Filippo, Ramirez Morales, Rafael, Cillo, Umberto, Trevisani, Franco, Miele, Luca, Marchesini, Giulio, Farinati, Fabio

المساهمون: Vitale, Alessandro, Svegliati-Baroni, Gianluca, Ortolani, Alessio, Cucco, Monica, Dalla Riva, Giulio V, Giannini, Edoardo G, Piscaglia, Fabio, Rapaccini, Gianludovico, Di Marco, Mariella, Caturelli, Eugenio, Zoli, Marco, Sacco, Rodolfo, Cabibbo, Giuseppe, Marra, Fabio, Mega, Andrea, Morisco, Filomena, Gasbarrini, Antonio, Foschi, Francesco Giuseppe, Missale, Gabriele, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Azzaroli, Francesco, Vidili, Gianpaolo, Oliveri, Filippo, Pelizzaro, Filippo, Ramirez Morales, Rafael, Cillo, Umberto, Trevisani, Franco, Miele, Luca, Marchesini, Giulio, Farinati, Fabio

مصطلحات موضوعية: hepatocellular carcinoma, nonalcoholic steatohepatitis

الوصف: Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) represents a new inclusive definition of the whole spectrum of liver diseases associated to metabolic disorders. The main objective of this study was to compare patients with MAFLD and non-MAFLD with hepatocellular carcinoma (HCC) included in a nationally representative cohort. Methods: We analysed 6882 consecutive patients with HCC enrolled from 2002 to 2019 by 23 Italian Liver Cancer centres to compare epidemiological and future trends in three subgroups: pure, single aetiology MAFLD (S-MAFLD); mixed aetiology MAFLD (metabolic and others, M-MAFLD); and non-MAFLD HCC. Results: MAFLD was diagnosed in the majority of patients with HCC (68.4%). The proportion of both total MAFLD and S-MAFLD HCC significantly increased over time (from 50.4% and 3.6% in 2002-2003, to 77.3% and 28.9% in 2018-2019, respectively, p<0.001). In Italy S-MAFLD HCC is expected to overcome M-MAFLD HCC in about 6 years. Patients with S-MAFLD HCC were older, more frequently men and less frequently cirrhotic with clinically relevant portal hypertension and a surveillance-related diagnosis. They had more frequently large tumours and extrahepatic metastases. After weighting, and compared with patients with non-MAFLD, S-MAFLD and M-MAFLD HCC showed a significantly lower overall (p=0.026, p=0.004) and HCC-related (p<0.001, for both) risk of death. Patients with S-MAFLD HCC showed a significantly higher risk of non-HCC-related death (p=0.006). Conclusions: The prevalence of MAFLD HCC in Italy is rapidly increasing to cover the majority of patients with HCC. Despite a less favourable cancer stage at diagnosis, patients with MAFLD HCC have a lower risk of HCC-related death, suggesting reduced cancer aggressiveness.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/34933916; info:eu-repo/semantics/altIdentifier/wos/WOS:000733795700001; volume:72; issue:1; firstpage:141; lastpage:152; numberofpages:12; journal:GUT; https://hdl.handle.net/11577/3466706Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85145425936

الإتاحة: https://doi.org/10.1136/gutjnl-2021-324915Test
https://hdl.handle.net/11577/3466706Test

المؤلفون: Macaluso, Fabio Salvatore, Principi, Mariabeatrice, Facciotti, Federica, Contaldo, Antonella, Todeschini, Alessia, Saibeni, Simone, Bezzio, Cristina, Castiglione, Fabiana, Nardone, Olga Maria, Spagnuolo, Rocco, Fantini, Massimo Claudio, Riguccio, Gaia, Caprioli, Flavio, Viganò, Chiara, Felice, Carla, Fiorino, Gionata, Correale, Carmen, Bodini, Giorgia, Milla, Monica, Scardino, Giulia, Vernero, Marta, Desideri, Federico, Mannino, Mariella, Rizzo, Giuseppe, Orlando, Ambrogio

المساهمون: Macaluso, Fabio Salvatore, Principi, Mariabeatrice, Facciotti, Federica, Contaldo, Antonella, Todeschini, Alessia, Saibeni, Simone, Bezzio, Cristina, Castiglione, Fabiana, Nardone, Olga Maria, Spagnuolo, Rocco, Fantini, Massimo Claudio, Riguccio, Gaia, Caprioli, Flavio, Viganò, Chiara, Felice, Carla, Fiorino, Gionata, Correale, Carmen, Bodini, Giorgia, Milla, Monica, Scardino, Giulia, Vernero, Marta, Desideri, Federico, Mannino, Mariella, Rizzo, Giuseppe, Orlando, Ambrogio

مصطلحات موضوعية: Biologic, SARS-CoV-2, Vaccines

الوصف: Background: Patients on immunosuppressive drugs have been excluded from COVID-19 vaccines trials, creating concerns regarding their efficacy. Aims: To explore the humoral response to COVID-19 vaccines in patients with inflammatory bowel dis-ease (IBD) Methods: E ffectiveness and S af ety of C OVID-19 V a ccine in P ati e nts with Inflammatory B owel D isease (IBD) Treated with Immunomodulatory or Biological Drugs (ESCAPE-IBD) is a prospective, multicentre study promoted by the Italian Group for the study of Inflammatory Bowel Disease. We present data on serological response eight weeks after the second dose of COVID-19 vaccination in IBD patients and healthy controls (HCs).Results: 1076 patients with IBD and 1126 HCs were analyzed. Seropositivity for anti-SARS-CoV-2 IgG was reported for most IBD patients, even if with a lesser rate compared with HCs (92.1% vs. 97.9%; p < 0.001). HCs had higher antibody concentrations (median OD 8.72 [IQR 5.2-14-2]) compared to the whole co-hort of IBD patients (median OD 1.54 [IQR 0.8-3.6]; p < 0.001) and the subgroup of IBD patients (n = 280) without any treatment or on aminosalicylates only (median OD 1.72 [IQR 1.0-4.1]; p < 0.001). Conclusions: Although most IBD patients showed seropositivity after COVID-19 vaccines, the magni-tude of the humoral response was significantly lower than in HCs. Differently from other studies, these findings seem to be mostly unrelated to the use of immune-modifying treatments (ClinicalTri-als.govID:NCT04769258).(c) 2022 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36127228; info:eu-repo/semantics/altIdentifier/wos/WOS:000927018700001; volume:55; issue:2; firstpage:154; lastpage:159; numberofpages:6; journal:DIGESTIVE AND LIVER DISEASE; https://hdl.handle.net/11577/3474429Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85138024171

الإتاحة: https://doi.org/10.1016/j.dld.2022.08.027Test
https://hdl.handle.net/11577/3474429Test